Literature DB >> 7921208

Effect of growth hormone treatment on insulin secretion and glucose metabolism in prepubertal boys with short stature.

J Aman1, S Rosberg, K Albertsson-Wikland.   

Abstract

The purpose of this study was to evaluate the effect on insulin secretion and glucose metabolism of daily growth hormone (GH) treatment, 0.1 U/kg, for up to 3 years in 42 short prepubertal boys without GH deficiency. Their median height standard deviation (SD) score increased from -2.7 to -1.7, whereas their weight for height SD score was unchanged after 3 years of treatment. Fasting plasma glucose concentrations were unchanged, but median fasting insulin concentrations increased from 6.0 mU/l before treatment to 7.8 mU/l (p < 0.05) after the first year. No further increase was seen during the second or third years. The median insulin area under the curve 10-60 min after an intravenous glucose tolerance test increased from 480 mU.l-1.min-1 before treatment to 799 mU.l-1.min-1 (p < 0.05) after 1 year. The median glucose disposal rate (K value) before GH treatment, 2.2%/min, was unchanged after 1 year of treatment. A significant positive correlation was found between the change in the height SD score and the change in fasting insulin concentration during the first (r = 0.45; p < 0.01) and second (r = 0.56; p < 0.05) years of GH treatment. It was concluded that GH treatment in prepubertal children without GH deficiency caused a moderate increase in fasting and stimulated insulin concentrations during the first year of treatment. There was no further change during the following years of treatment, and there were no negative effects on fasting plasma glucose concentrations or glucose disposal rates. The increase in insulin concentration was related positively to the growth response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921208     DOI: 10.1530/eje.0.1310246

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  2 in total

1.  Different thresholds of tissue-specific dose-responses to growth hormone in short prepubertal children.

Authors:  Ralph Decker; Anders Nygren; Berit Kriström; Andreas Fm Nierop; Jan Gustafsson; Kerstin Albertsson-Wikland; Jovanna Dahlgren
Journal:  BMC Endocr Disord       Date:  2012-11-01       Impact factor: 2.763

2.  Efficacy and safety of Samtropin™ recombinant human growth hormone; a double-blind randomized clinical trial.

Authors:  Ozra Tabatabaei-Malazy; Mohammad Reza Mohajeri-Tehrani; Ramin Heshmat; Eghbal Taheri; Gita Shafiee; Maryam Razzaghy-Azar; Ali Rabbani; Mostafa Qorbani; Hossein Adibi; Samimeh Shahbazi; Farzaneh Karimi; Sheema Rezaian; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2014-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.